ISTH DIC subcommittee communication on anticoagulation in COVID‐19-Reference-Cited by-同舟云学术

ISTH DIC subcommittee communication on anticoagulation in COVID‐19

Published:2020-08-31 Issue:9 Volume:18 Page:2138-2144
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Thachil Jecko¹,Juffermans Nicole P.²³,Ranucci Marco⁴^ORCID,Connors Jean M.⁵^ORCID,Warkentin Theodore E.⁶⁷^ORCID,Ortel Thomas L.⁸^ORCID,Levi Marcel⁹,Iba Toshiaki¹⁰^ORCID,Levy Jerrold H.¹¹

Affiliation:

1. Department of Haematology Manchester University Hospitals Manchester UK

2. Laboratory of Experimental Intensive Care and Anesthesiology Amsterdam University Medical Center Amsterdam The Netherlands

3. Department of Intensive Care OLVG Hospital Amsterdam The Netherlands

4. Department of Cardiovascular Anesthesia and ICU IRCCS Policlinico San Donato San Donato Milanese (Milan Italy

5. Hematology Division Dana‐Farber Cancer Institute Brigham and Women's Hospital Boston MA USA

6. Department of Pathology and Molecular Medicine McMaster University Hamilton ON Canada

7. Department of Medicine McMaster University Hamilton ON Canada

8. Division of Hematology Departments of Medicine and Pathology Duke University Medical Center Durham NC USA

9. Department of Medicine and Cardiometabolic Programme‐NIHR UCLH/UCL BRC University College London Hospitals NHS Foundation Trust London London UK

10. Department of Emergency and Disaster Medicine Juntendo University Graduate School of Medicine Tokyo Japan

11. Departments of Anesthesiology, Critical Care and Surgery Duke University School of Medicine Durham NC USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15004

Reference55 articles.

1. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

2. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19;Klok FA;Thromb Res,2020

3. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

4. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19

5. Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venous thrombosis and embolism in surgical hospital patients in the conditions of the COVID-19 pandemic;EMERGENCY MEDICINE;2024-07-02

2. CD66b⁺/CD68⁺ circulating extracellular vesicles, lactate dehydrogenase and neutrophil‐to‐lymphocyte ratio can differentiate coronavirus disease 2019 severity during and after infection;Journal of Extracellular Vesicles;2024-07

3. Clinical decision support to enhance venous thromboembolism pharmacoprophylaxis prescribing for pediatric inpatients with COVID‐19;Pediatric Blood & Cancer;2024-01-03

4. Rapid Disappearance of Lupus Anticoagulant in COVID-19 Infection;Clinical & Experimental Thrombosis and Hemostasis;2023-10-10

5. The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases;International Journal of Molecular Sciences;2023-08-14